Upgrade to SI Premium - Free Trial

Organogenesis Holding (ORGO)

1.71 +0.07 (4.27%)

Chart
Today 6M 1Y 5Y

Upcoming Events

- Earnings (11/5/26)

Latest Headlines

Form 8-K Organogenesis Holdings For: Aug 06 August 11, 2026 10:27 AM - SEC Filing Form 424B5 Organogenesis Holdings August 11, 2026 10:27 AM - SEC Filing Form 8-K Organogenesis Holdings For: Aug 06 August 6, 2026 4:46 PM - SEC Filing Form 424B5 Organogenesis Holdings August 6, 2026 4:44 PM - SEC Filing Organogenesis Holding (ORGO) Misses Q2 EPS by 42c August 6, 2026 4:42 PM - StreetInsider Form 10-Q Organogenesis Holdings For: Jun 30 August 6, 2026 4:21 PM - SEC Filing Form 8-K Organogenesis Holdings For: Aug 06 August 6, 2026 4:17 PM - SEC Filing Organogenesis Holdings Inc. Reports Second Quarter 2026 Financial Results August 6, 2026 4:06 PM - StreetInsider Organogenesis publishes Affinity trial results for venous leg ulcers July 27, 2026 4:05 PM - StreetInsider Organogenesis Announces Publication of Peer-Reviewed Clinical Trial Results Demonstrating Clinical Benefit of Affinity™ in the Most Challenging and Complex Venous Leg Ulcers July 27, 2026 4:05 PM - StreetInsider Organogenesis Holdings Inc. to Report Second Quarter of Fiscal Year 2026 Financial Results on August 6, 2026 July 9, 2026 7:30 AM - StreetInsider FDA accepts Organogenesis BLA for knee osteoarthritis treatment ReNu July 6, 2026 4:05 PM - StreetInsider Organogenesis Announces FDA Acceptance of Biologics License Application for ReNu® for the Management of Symptomatic Knee Osteoarthritis July 6, 2026 4:05 PM - StreetInsider Regenerative Medicine’s Next Chapter: Inside the Race to Make the Body Rebuild Itself June 18, 2026 12:43 PM - StreetInsider Form 8-K Organogenesis Holdings For: Jun 15 June 16, 2026 4:33 PM - SEC Filing The Quiet Revolution in Regenerative Medicine: From Replacing Tissue to Rebuilding It June 16, 2026 10:30 AM - StreetInsider Full Article List